|
**Overview**: B-CLL MRD Monitoring Panel**Introduction**: The B-CLL MRD Monitoring Panel is a diagnostic tool designed to monitor B-cell chronic lymphocytic leukemia residual disease using whole blood or bone marrow samples. In India, CLL is the most common adult leukemia in older age groups (~4-5 per 100,000 elderly), with MRD negativity post-therapy (ibrutinib, venetoclax, chemoimmunotherapy) strongly predicting prolonged progression-free survival. High morbidity from under-monitoring in rural/low-SES elderly patients, limited molecular/flow labs, delayed detection of relapse leading to disease progression, infections, or Richter transformation. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs PCR for B-CLL-specific markers (IGH rearrangements, IGHV mutation status) and MRD quantification over 1-2 days with high sensitivity (10^-4 to 10^-5), valuable for assessing deep response and guiding treatment discontinuation or escalation. This diagnostic falls under leukemia monitoring and targets CLL patients in remission or on targeted therapy, addressing accurate detection to optimize therapy duration and reduce relapse risk. With elevated morbidity due to under-monitoring, the test supports public health efforts by enabling precise MRD assessment and improving long-term CLL outcomes. Its blood/bone marrow-based approach ensures reliable quantification.**Other Names**: B-CLL MRD Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/hematology/oncology, compliant with 2025 standards.**Historical Milestone**: MRD PCR in CLL standard since 2010s; in India, expanding in hematology centers.**Purpose**: The test assesses 2 parameters including B-CLL-specific markers to guide MRD monitoring, detect residual disease, inform therapy adjustment.**Test Parameters**: 1. B-CLL-Specific Markers, 2. MRD Quantification.**Pretest Condition**: No fasting required; patients should be CLL in remission or post-treatment.**Specimen**: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve DNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on treatment phase, prior MRD.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected MRD including relapse, benefits of monitoring, and minimal discomfort from sampling.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and quantify MRD within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low disease burden can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Detectable MRD indicates higher relapse risk, necessitating specialist input.**Specialist Consultation**: Hematologists/oncologists should be consulted for management.**Additional Supporting Tests**: Flow cytometry MRD, IGHV status for confirmation.**Test Limitations**: Marker-specific; comprehensive approach required.**References**: Indian Journal of Hematology 2024, Leukemia Studies India 2023. |
